Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Barbara Ann Karmanos Cancer Institute
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Lawrence Lum, Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier:
NCT01147016
First received: June 17, 2010
Last updated: September 9, 2013
Last verified: September 2013

June 17, 2010
September 9, 2013
July 2010
June 2015   (final data collection date for primary outcome measure)
  • Pathologic complete response [ Time Frame: Every 8 weeks or as indicated ] [ Designated as safety issue: No ]
  • Recurrence-free survival [ Time Frame: Every 8 weeks or as indicated ] [ Designated as safety issue: No ]
  • Pathologic complete response [ Designated as safety issue: No ]
  • Recurrence-free survival [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01147016 on ClinicalTrials.gov Archive Site
Overall survival [ Time Frame: Every 3 months for the first year, and then every 6 months for one more year. ] [ Designated as safety issue: No ]
Overall survival [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery
A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers

RATIONALE: Neoadjuvant chemotherapy for women with stage II-III Her negative breast cancer followed by Her2Bi armed activated T cells (ATCs) may significantly improve the pathologic complete response (pCR) rate at the time of surgery. Arming ex vivo expanded T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Giving combination neoadjuvant chemotherapy followed by laboratory-treated T cells before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II clinical trial is studying how well giving laboratory-treated T cells after neoadjuvant chemotherapy works in treating women with stage II or stage III breast cancer undergoing surgery.

OBJECTIVES:

  • To determine, in a phase II clinical trial of women with stage II-III triple-negative breast cancer, if a regimen of neoadjuvant chemotherapy followed by HER2Bi-armed activated T cells (ATCs) improves the pathologic complete response (pCR) rate at the time of surgery.
  • To investigate the association between pCR and clinical responses (disease-free survival and overall survival).
  • To determine if HER2Bi-armed ATCs administered after neoadjuvant chemotherapy will modulate the cytotoxicity of lymphocytes in the blood and tumor-infiltrating lymphocytes.
  • To determine if there is an association between systemic and tumor site anti-tumor responses.
  • To determine if HER2Bi-armed ATCs administered after neoadjuvant chemotherapy decreases the frequency and colony-forming ability of the putative breast cancer stem cells in the tumor tissue at the time of surgery compared to that obtained in the tumor biopsy after chemotherapy.
  • To investigate the association between the observed changes in numbers and proportion of CD44^hi/CD24^lo, CD133, aldehyde dehydrogenase activity (ALDH1)-positive cells and the pCR.

OUTLINE: This is a multicenter study.

  • Neoadjuvant chemotherapy: Patients receive doxorubicin hydrochloride and cyclophosphamide every 2 weeks for 4 doses. Patients then receive paclitaxel once a week for 12 doses.
  • Neoadjuvant immunotherapy: Beginning 3-6 days after the last dose of chemotherapy, patients receive autologous HER2Bi-armed activated T cells (ATCs) IV over 30-60 minutes once a week for 4 weeks.
  • Surgery: Approximately 2 weeks after the last dose of HER2Bi-armed ATCs, patients undergo standard surgery.

Tissue and blood samples are collected periodically for correlative immune function tests.

After completion of study treatment, patients are followed up every 8 weeks for 48 weeks and then every 3 months thereafter.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Biological: HER2Bi-armed activated T cells
    Total of 4 of the T cell infusions intravenously over a period of 1 month.
  • Drug: cyclophosphamide
    As prescribed by physician, standard of care.
    Other Name: Cytoxan®
  • Drug: doxorubicin hydrochloride
    As prescribed by physician, standard of care.
    Other Names:
    • Adriamycin®
    • Rubex®
  • Drug: paclitaxel
    As prescribed by physician, standard of care.
    Other Names:
    • Abraxane®
    • Onxol®
    • Taxol
  • Other: laboratory biomarker analysis
    Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
  • Procedure: neoadjuvant therapy
    As prescribed by physician, standard of care.
  • Procedure: therapeutic conventional surgery
    As recommended by physician, post immunotherapy.
Experimental: HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy

HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month

Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care.

Interventions:
  • Biological: HER2Bi-armed activated T cells
  • Drug: cyclophosphamide
  • Drug: doxorubicin hydrochloride
  • Drug: paclitaxel
  • Other: laboratory biomarker analysis
  • Procedure: neoadjuvant therapy
  • Procedure: therapeutic conventional surgery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
48
Not Provided
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Signed and dated institutional review board (IRB)-approved consent form
  • Women of reproductive potential must agree to use an effective nonhormonal method of contraception during therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and/or Karnofsky PS of >= 70%
  • Diagnosis of invasive adenocarcinoma of the breast made by core needle biopsy
  • Palpable primary breast tumor measuring >= 2.0 cm on physical exam or imaging
  • Patients with stage II-IIIA breast cancer that is HER2-negative by immunohistochemistry (IHC) (0-2+) or fluorescence in situ hybridization (FISH) (HER2/chromosome enumeration probe [CEP]17 amplification ratio < 2.2) for whom definitive surgical treatment after "third generation" neoadjuvant chemoT is planned; Patients with HER2 (3+) cancer by IHC that also demonstrate a FISH ratio <2.2 are also eligible. Estrogen receptor (ER) or progesterone receptor (PR) status can be positive or negative; the receptor status needs to be recorded
  • Patients may have lymph node positive or negative disease, as long as they have clinical stage II or IIIA breast cancer; patients may have the lymph nodes assessed by any method deemed appropriate by the treating physicians, including pre-neoadjuvant therapy sentinel lymph node biopsy
  • Patients must discontinue sex hormone therapy prior to registration, e.g. birth control pills, hormonal replacement therapy
  • Absolute neutrophil count (ANC) must be >= 1200/mm^3
  • Platelet count must be >= 100,000/mm^3
  • Hemoglobin must be >= 9.0 mg/dL
  • Total bilirubin must be =< the upper limit of normal (ULN) for the lab unless the patient has a grade 1 bilirubin elevation (> ULN to 1.5 x ULN) resulting from Gilbert's disease or similar syndrome due to slow conjugation of bilirubin; and
  • Alkaline phosphatase must be =< 2.5 x ULN for the lab
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) must be =< 1.5 x ULN for the lab
  • Alkaline phosphatase and AST/ALT may not both be > the ULN; for example, if the alkaline phosphatase is > the ULN but =< 2.5 x ULN, then the AST/ALT must be =< the ULN; if the AST/ALT is > the ULN but =< 1.5 x ULN, then the alkaline phosphatase must be =< ULN
  • Patients with either skeletal pain or alkaline phosphatase that is > ULN must have a bone scan showing they do not have metastatic disease; suspicious findings on bone scan must be confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy
  • Patients with AST/ALT or alkaline phosphatase > ULN must have liver imaging that does not demonstrate metastatic disease
  • Patients with AST/ALT > ULN must have negative hepatitis studies
  • Patients with stage II disease and clinical suspicion for metastatic disease based on reported symptoms, physical examination findings, or laboratory abnormalities must have staging studies demonstrating no evidence of metastatic disease (with exception of axillary lymph nodes or mammary nodes); patients with stage IIIA disease must have staging studies demonstrating no evidence of metastatic disease (with exception of axillary lymph nodes or mammary nodes), even if asymptomatic with normal physical examination and laboratory values; such staging studies must include: chest imaging (chest X-ray, computed tomography [CT], or MRI), abdominal/pelvis imaging (CT or MRI), and bone imaging (bone scan or positron emission tomography [PET]-scan); abnormalities that are indeterminate and too small to biopsy should be followed with further imaging, as appropriate, but do not exclude patients from the study; abnormalities that are suspicious and large enough to biopsy exclude patients from the study, unless a biopsy is performed and is negative for metastatic disease
  • Serum creatinine =< 1.5 x ULN for the lab
  • Pre-entry core biopsy with sufficient material for correlative studies
  • Left Ventricular Ejection Fraction (LVEF) >= 50 % (by multigated acquisition scan [MUGA] or echocardiography)

Exclusion Criteria

  • Tumor determined to be HER2-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (HER2/CEP17 amplification ratio >= 2.0)
  • Tumors clinically staged as T4 or N3
  • Definitive evidence of metastatic disease with exception of axillary lymph nodes or mammary nodes
  • Synchronous bilateral breast cancer (invasive or ducal carcinoma in situ [DCIS])
  • Treatment including radiation therapy, chemoT, biotherapy, and/or hormonal therapy for the currently diagnosed breast cancer prior to study entry
  • Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible if this therapy is discontinued 1 week prior to registration)
  • Prior history of invasive breast cancer (Patients with a history of DCIS or lobular carcinoma in situ [LCIS] are eligible)
  • Prior therapy with anthracyclines for any malignancy
  • Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by the physician to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell or squamous cell carcinoma of the skin
  • Known cardiac disease that would preclude the use of anthracyclines; this includes:

    • Angina pectoris that requires the use of anti-anginal medication
    • History of documented congestive heart failure
    • Serious cardiac arrhythmia requiring medication
    • Severe conduction abnormality
    • Valvular disease with documented cardiac function compromise; and
    • Uncontrolled hypertension defined as blood pressure (BP) that is consistently > 150/90 on antihypertensive therapy at the time of registration (Patients with hypertension that is well controlled on medication are eligible)
  • History of myocardial infarction (MI) documented by elevated cardiac enzymes with persistent regional wall motion abnormality on assessment of left ventricular (LV) function (Patients with history of MI must have an echo instead of/in addition to a MUGA to evaluate LV wall motion)
  • Symptomatic peripheral vascular disease
  • Sensory/motor neuropathy >= grade 2, as defined by the National Cancer Institute (NCI)'s Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0)
  • Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up
  • Chronic ongoing steroid use at the time of registration for any condition (such as asthma, rheumatoid arthritis, etc)
  • Administration of any investigational agents within 30 days before study entry
  • Pregnancy or lactation at the time of registration
  • Psychiatric or addictive disorders or other conditions that in the opinion of the investigators would preclude the patient from complying with the study protocol.

Minor changes from these guidelines will be allowed at the discretion of the research team under special circumstances. The reasons for exceptions will be documented

Female
18 Years and older
No
United States
 
NCT01147016
CDR0000675211, P30CA022453, WSU-2010-056
Yes
Lawrence Lum, Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Lawrence Lum, M.D. Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP